Amakem's lead product, AMA0076, is a Rho Kinase (ROCK) inhibitor which is currently in a Phase 2a clinical trial in glaucoma and ocular hypertension. Its primary mode of action is through increasing flow of aqueous humor via the trabecular meshwork.
Amakem is an ophthalmology company developing new treatments for serious eye conditions. Amakem's product pipeline is based on its unique Localized Drug Action platform which is designed to generate safe and effective novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects. Amakem's lead candidate, AMA0076, is for glaucoma and entered Phase 2a development late last year. The Company is also working to apply the Localized Drug Action approach to a range of other eye diseases.
Founded in 2010, Amakem has raised more than €21m in funding and is backed by leading life sciences investors including Forbion, Omnes Capital (previously Crédit Agricole), Vesalius BioCapital, LRM, PMV/Vinnof and Life Science Research Partners.Amakem is based in Belgium and located in the life sciences incubator "BioVille" at the University of Hasselt. The Company has a long-standing collaboration with the Ophthalmology Research Center of the University Leuven Hospital, where it sponsors a Chair in Ophthalmology Translational Research. For more information, please contact Amakem NV Jack Elands, CEO email@example.com +32-(0)-474-828-580 Citigate Dewe Rogerson Chris Gardner/ Nina Enegren firstname.lastname@example.org email@example.com +44-(0)-20-7638-9571 SOURCE Amakem